|
Market Closed -
Nasdaq
00:00:00 15/07/2026 +04
|
5-day change | 1st Jan Change | ||
| 31.49 USD | +0.03% |
|
-.--% | +34.92% |
| 08-03 | CDP targets new defense acquisitions after T-Defence deal - sources | RE |
| 08-03 | CDP's new chapter, a push for global companies | AN |
Company Valuation: Catalyst Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 346.2 | 698.1 | 1,936 | 1,792 | 2,489 | 2,869 |
| Change | - | 101.66% | 177.28% | -7.42% | 38.9% | 15.25% |
| Enterprise Value (EV) 1 | 205.9 | 511 | 1,641 | 1,658 | 1,975 | 2,162 |
| Change | - | 148.16% | 221.15% | 1.03% | 19.11% | 9.5% |
| P/E | 4.7x | 18.3x | 24.8x | 26.7x | 15.9x | 13.9x |
| PBR | 2.04x | 3.37x | 6.52x | 4.64x | 3.47x | 3x |
| PEG | - | -0.4x | 0x | -1.7x | 0x | 0.5x |
| Capitalization / Revenue | 2.91x | 4.96x | 9.04x | 4.5x | 5.06x | 4.87x |
| EV / Revenue | 1.73x | 3.63x | 7.66x | 4.16x | 4.02x | 3.67x |
| EV / EBITDA | 4.97x | 9.72x | 15.9x | 13.9x | 8.48x | 7.31x |
| EV / EBIT | 4.99x | 9.76x | 16.1x | 19.1x | 10.1x | 8.39x |
| EV / FCF | 7.11x | 12.1x | 18.3x | -7.55x | 9.79x | 12.6x |
| FCF Yield | 14.1% | 8.25% | 5.47% | -13.2% | 10.2% | 7.92% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 0.71 | 0.37 | 0.75 | 0.63 | 1.31 | 1.68 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 119.1 | 140.8 | 214.2 | 398.2 | 491.7 | 589 |
| EBITDA 1 | 41.4 | 52.58 | 103.1 | 119.7 | 232.9 | 295.7 |
| EBIT 1 | 41.3 | 52.38 | 101.8 | 86.81 | 195.1 | 257.8 |
| Net income 1 | 74.98 | 39.48 | 83.08 | 71.41 | 163.9 | 214.3 |
| Net Debt 1 | -140.2 | -187.1 | -294.5 | -134.1 | -514.4 | -706.4 |
| Reference price 2 | 3.34 | 6.77 | 18.60 | 16.81 | 20.87 | 23.34 |
| Nbr of stocks (in thousands) | 103,648 | 103,118 | 104,071 | 106,611 | 119,273 | 122,912 |
| Announcement Date | 15/03/21 | 16/03/22 | 15/03/23 | 28/02/24 | 26/02/25 | 25/02/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 3.85B | |
| 18.39x | 4.28x | 10.08x | 0.49% | 79.3B | |
| 20.35x | 4.33x | 13.36x | 2.44% | 59.21B | |
| -16.37x | 24.54x | -15.89x | -.--% | 55.09B | |
| 36.19x | 12.33x | 23.67x | -.--% | 49.86B | |
| 21.68x | 4.79x | 13.66x | 0.67% | 47.9B | |
| 38.82x | 3.56x | 13.58x | -.--% | 32.28B | |
| 55.5x | 3.53x | 27.36x | -.--% | 25.21B | |
| 71.76x | 7.68x | 46.71x | -.--% | 23.87B | |
| 24.44x | 5.24x | 13.65x | -.--% | 16.89B | |
| Average | 30.08x | 7.81x | 16.24x | 0.4% | 39.35B | |
| Weighted average by Cap. | 24.08x | 8.39x | 12.89x | 0.55% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CPRX Stock
- Valuation Catalyst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
